Hematologic Malignancies Market Size, Share & Trends Analysis Report By Disease (Leukemia, Lymphoma), By Therapy (Chemotherapy, Immunotherapy), By End Use, By Region, And Segment Forecasts, 2024

Description

Hematologic Malignancies Market Growth & Trends:

The global hematologic malignancies market size is estimated to reach USD 113.89 billion in 2030 and is projected to grow at a CAGR of 8.0% from 2024 to 2030. Increasing incidence of hematologic malignancies and presence of a strong product pipeline are estimated to boost the market. Moreover, increasing number of mergers and acquisitions are also expected to accelerate growth.

Furthermore, governments of developing countries are spending more on healthcare and on improving healthcare infrastructure. This is likely to reduce out-of-pocket expenditure for patients. which is considered as one of the major factors driving the hematologic malignancies market.

Recently it has been seen that the government sources are taking an initiative in funding the institutes for breakthrough oncology research. This is a major growth driver for the market as it will support the institutes to conduct their research on a larger-scale without any financial constraints. Federal government funding for research in oncology has led to a substantial development in cancer detection, prevention, diagnosis, treatment and quality of life for patients. Due to the advancement in cancer research, more patients with cancer are being successfully treated. The increasing investment in cancer research is expected to boost the growth of market during forecast period

Hematologic Malignancies Market Report Highlights:

Multiple myeloma is expected to be one of the fastest growing segments over the forecast period owing to strong pipeline of blockbuster products
Chronic myeloid leukemia was identified as the largest leukemia subtype in 2016 due to availability of large number of products and high number of target population
Chemotherapy held the largest share in 2016 on the basis of therapy due to its preference as first line of therapy and wide product range
Immunotherapy is anticipated to be the fastest growing segment and this can be attributed to lower adverse effects and higher efficiency
North America dominated the market in 2016 owing to local presence of key players and increasing number of mergers and acquisitions
Asia Pacific is expected to be the fastest growing region over the next decade with lucrative CAGR from 2017 to 2025 due to improving economic conditions and rising healthcare expenditure
Some of the key players are Pfizer, Inc.; F. Hoffmann-LA Roche Ltd; Sanofi; Bristol-Myers Squibb Company; AbbVie, Inc.; Novartis AG; GlaxoSmithKline PLC; Celgene Corporation; Johnson & Johnson Services, Inc.; and Takeda Pharmaceutical Company Limited
Most of the key players are focusing on expanding their product portfolios, development of new treatment, and acquisitions.

Product Code: GVR-1-68038-687-5

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Hematologic Malignancies Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Hematologic Malignancies Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Hematologic Malignancies Market: Disease Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Hematologic Malignancies Market: Disease Movement Analysis, 2023 & 2030 (USD Million)
4.3. Leukemia
- 4.3.1. Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Lymphoma
- 4.4.1. Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Myeloma
- 4.5.1. Myeloma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Hematologic Malignancies Market: Therapy Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Hematologic Malignancies Market: Therapy Movement Analysis, 2023 & 2030 (USD Million)
5.3. Chemotherapy
- 5.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Immunotherapy
- 5.4.1. Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Targeted Therapy
- 5.5.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Other Therapies
- 5.6.1. Other Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Hematologic Malignancies Market: End Use Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Hematologic Malignancies Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
6.3. Hospital Pharmacies
- 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Retail Pharmacies
- 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Other
- 6.5.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Hematologic Malignancies Market: Regional Estimates & Trend Analysis

7.1. Hematologic Malignancies Market Share, By Region, 2023 & 2030 (USD Million)
7.2. North America
- 7.2.1. North America Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.2. U.S.
  - 7.2.2.1. U.S. Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.3. Canada
  - 7.2.3.1. Canada Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.4. Mexico
  - 7.2.4.1. Mexico Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
- 7.3.1. Europe Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. U.K.
  - 7.3.2.1. U.K. Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Germany
  - 7.3.3.1. Germany Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. France
  - 7.3.4.1. France Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.5. Italy
  - 7.3.5.1. Italy Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.6. Spain
  - 7.3.6.1. Spain Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.7. Denmark
  - 7.3.7.1. Denmark Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.8. Sweden
  - 7.3.8.1. Sweden Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.9. Norway
  - 7.3.9.1. Norway Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
- 7.4.1. Asia Pacific Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. Japan
  - 7.4.2.1. Japan Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. China
  - 7.4.3.1. China Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. India
  - 7.4.4.1. India Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.5. Australia
  - 7.4.5.1. Australia Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.6. South Korea
  - 7.4.6.1. South Korea Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.7. Thailand
  - 7.4.7.1. Thailand Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
- 7.5.1. Latin America Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Brazil
  - 7.5.2.1. Brazil Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Argentina
  - 7.5.3.1. Argentina Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. South Africa
  - 7.6.2.1. South Africa Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. Saudi Arabia
  - 7.6.3.1. Saudi Arabia Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. UAE
  - 7.6.4.1. UAE Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Kuwait
  - 7.6.5.1. Kuwait Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
- 8.4.1. Pfizer Inc.
  - 8.4.1.1. Participant's Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Recent Developments/ Strategic Initiatives
- 8.4.2. F. Hoffmann-LA Roche Ltd
  - 8.4.2.1. Participant's Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Recent Developments/ Strategic Initiatives
- 8.4.3. Sanofi SA
  - 8.4.3.1. Participant's Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Recent Developments/ Strategic Initiatives
- 8.4.4. Bristol-Myers Squibb Company
  - 8.4.4.1. Participant's Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Recent Developments/ Strategic Initiatives
- 8.4.5. AbbVie Inc.
  - 8.4.5.1. Participant's Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Recent Developments/ Strategic Initiatives
- 8.4.6. Novartis AG
  - 8.4.6.1. Participant's Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Recent Developments/ Strategic Initiatives
- 8.4.7. GlaxoSmithKline PLC
  - 8.4.7.1. Participant's Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Recent Developments/ Strategic Initiatives
- 8.4.8. Amgen Inc.
  - 8.4.8.1. Participant's Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Recent Developments/ Strategic Initiatives
- 8.4.9. Takeda Pharmaceutical Co. Ltd
  - 8.4.9.1. Participant's Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Recent Developments/ Strategic Initiatives
- 8.4.10. Johnson & Johnson
  - 8.4.10.1. Participant's Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Recent Developments/ Strategic Initiatives

Hematologic Malignancies Market Size, Share & Trends Analysis Report By Disease (Leukemia, Lymphoma), By Therapy (Chemotherapy, Immunotherapy), By End Use, By Region, And Segment Forecasts, 2024 - 2030